姓 名 | 相小强 | 性 别 | 男 |
职 称 | 教授，博士生导师 | 学 历 | 博士 |
电 话 | 021-51980024 | 传 真 | 021-51980024 |
电子邮件 | xiangxq@fudan.edu.cn | 个人主页 | |
通讯地址 | 上海浦东张衡路826号科研楼东辅楼211室 邮编：201203 | ||
个人简介
教授，博士生导师，临床药理学博士。复旦大学药学院临床药学与药事管理系副主任（主持工作）。1999年本科毕业于北京大学药学院，2006年获新加坡国立大学药学硕士，2012年获赫尔辛基大学临床药理学博士。2005年～2007年在新加坡国立癌症中心和新加坡CombinatoRx公司分别从事临床研究和新药研发工作。现主要研究方向为定量药理学、药物相互作用和药物基因组学。担任中国药理学会定量药理专业委员会常务委员、中国药理学会表观遗传药理专业委员会委员、中国药理学会药物代谢专业委员会委员、中国药理学会治疗药物监测研究专业委员会定量药理学组委员和上海药理学会药物代谢专业委员会副主任委员。主持各类纵向科研项目11项，其中国家自然科学基金项目3项，省部级基金项目4项，校院级基金项目4项。发表SCI论文78篇和中文核心期刊论文22篇，已授权国家专利2项和软件著作权5项，主编英文专著1本，副主编中文专著1本，参编中英文专著和教材4本。担任《药学学报》杂志编委。参与编写多项CDE指导原则和中国专家共识。
教育经历
2008–2012，赫尔辛基大学，临床药理系，博士
2002–2005，新加坡国立大学，药学系，硕士
1999–2002，上海医药工业研究院，制剂部，硕士
1995–1999，北京大学，药学院，学士工作经历
2022–今，复旦大学药学院，教授，博士生导师
2019-今，复旦大学药学院，临床药学与药事管理系副主任（主持工作）
2016-2019，复旦大学药学院，临床药学与药事管理教研室副主任
2012–2022，复旦大学药学院，副研究员，硕士生导师/博士生导师
2007，新加坡CombinatoRx公司，Associate Scientist
2005–2007，新加坡国立癌症中心，Research Officer研究方向
1. 定量药理学
2. 药物相互作用
3. 药物基因组学
主持的科研项目
1. 国家自然科学基金面上项目，82373952，项目名称：基于定量系统药理学模型和类器官的人促卵泡激素精准用药研究，2024-2027，主持。
2. 国家自然科学基金国际(地区)合作与交流项目，82011540409，题目：基于PBPK模型和IVIVE研究安罗替尼合用P450色素酶促变药时的药物相互作用和给药策略，2020-2022，主持。
3. 国家自然科学基金面上项目，81473409，项目名称：PBPK建模预测CYP3A5基因型对五酯胶囊和他克莫司药动相互作用的影响，2015-2018，主持。
4. 2023年度上海市法医学重点实验室暨司法部司法鉴定重点实验室开放课题，KF202304，项目名称：基于生理药动学模型和分子建模的U-47700 和苯二氮卓类药物的协同作用机制研究，2023-2025，主持。
5. 上海市2018年度“科技创新行动计划”实验动物研究领域项目，18140900900，项目名称：生理药动学模型结合体外动态Bio-PK/PD系统替代大鼠进行药代动力学研究，2018-2021，主持。
6. 2022年度上海市卫生健康委员会卫生行业临床研究专项面上项目，202240116，项目名称：基于PBPK模型的比马前列素眼睑给药研究，2023-2025,主持。
7. 2018年度上海市卫生行业临床研究专项面上项目，项目名称：201840057，基于代谢转运通路和Bio-PK/PD系统研究丙基硫氧嘧啶所致肝损伤的机制，2019-2021，主持。
8. The University of Sydney-Fudan University Partnership Collaboration Awards (PCA)2019 round, 项目名称：3D printed microneedle patches for personalized medicine，2019-2020，主持。
9. 复旦大学附属浦东医院-复旦大学药学院融和基金项目，RHJJ2017-05，项目名称：基于生理药动学模型的口粘膜剂的生物等效性豁免研究，2018-2019，主持。
10.复旦大学附属中山医院闵行分院-复旦大学药学院战略合作自主研究课题融合基金，RO-MY201710，项目名称：基于生理药动学模型研究阿托伐他汀和伏立康唑的精准联合用药，2018-2019，主持。
11. 2010年芬兰赫尔辛基Biomedicum Helsinki Foundation, 项目名称：Effects of genetic polymorphisms in SLCO1B1 and CYP7A1 on plasma bile acids in humans and the pharmacokinetics of therapeutic ursodeoxycholic acid”，主持。
主持教改项目
2015年：药学硕士专业学位研究生教育教学改革课题（全国药学专业学位研究生教育指导委员会），题目：基于标准化病人的临床药学实践能力考核指标的研究
发表论文
1) Prediction of Drug-Drug Interactions with Ensartinib as a Time Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model.Wang X, Yu Y, Liu H, Bu F, Shen C, He Q, Zhu X, Jiang P, Han B, Xiang X (通讯作者).Drug Metab Dispos. 2023;DMD-AR-2023-001373. doi: 10.1124/dmd.
2) Yuan Y, Han Y, Yap CW, Kochhar J, Li H, Xiang X (通讯作者), Kang L. Prediction of drug permeation through microneedled skin by machine learning. Bioeng Transl Med. 2023;e10512.
3) Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir. Yang W, Mak W, Gwee A, Gu M, Wu Y, Shi Y, He Q, Xiang X, Han B, Zhu X. Pharmaceutics. 2023;15(7):1801
4) Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.Wang X, Chen F, Guo N, Gu Z, Lin H, Xiang X, Shi Y, Han B.Cancer Chemother Pharmacol. 2023 Oct;92(4):253-270.
5) Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach.Pan C, Cheng Y, He Q, Li M, Bu F, Zhu X, Li X, Xiang X (通讯作者).Chem Biol Interact. 2023;373:110400.
6) Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization.Gu M, Li A, Mak W, Dong F, Xu N, Zhang J, Shi Y, Zheng N, Tang Z, He Q, Ruan C, Guo W, Xiang X, Wang C, Han B, Zhu X.Front Pharmacol. 2023;14:1089862.
7) Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model.Yuan Y, Li Z, Wang K, Zhang S, He Q, Liu L, Tang Z, Zhu X, Chen Y, Cai W, Peng C, Xiang X (通讯作者). Molecules. 2023;28(2):837.
8) Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. Ran XB, Ding LW, Sun QY, Yang H, Said JW, Zhentang L, Madan V, Dakle P, Xiao JF, Loh X, Li Y, Xu L, Xiang X, Wang LZ, Goh BC, Lin DC, Chng WJ, Tan SY, Jha S, Koeffler HP. Cancer Res. 2023 Mar 15;83(6):922-938.
9) Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling. Ji X, Meng X, He Q, Xiang X, Shi Y, Zhu X. Int J Mol Sci. 2023 Jan 1;24(1):757.
10) Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview. Jia Q, He Q, Yao L, Li M, Lin J, Tang Z, Zhu X, Xiang X (通讯作者). Molecules. 2022; 27(24):8670.
11) Applications of In Silico Models to Predict Drug-Induced Liver Injury.Lin J, Li M, Mak W, Shi Y, Zhu X, Tang Z, He Q, Xiang X (通讯作者). Toxics. 2022;10(12):788.
12) Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Feng Z, Li X, Tong WK, He Q, Zhu X, Xiang X, Tang Z. Front Pharmacol. 2022;13:894685.
13) Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib.Liu H, Yu Y, Liu L, Wang C, Guo N, Wang X, Xiang X (通讯作者), Han B.Front Pharmacol. 2022;13:970539.
14) Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.Wen HN, He QF, Xiang X (通讯作者), Jiao Z, Yu JG.Thromb Res. 2022;218:24-34.
15) Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae. Ji XW, Zhu X, Li Y, Xue F, Kuan IHS, He QF, Meng XR, Xiang X (通讯作者), Cui YM, Zheng B. Front Pharmacol. 2022 Jul 18;13:856792
16) Frailty in Community-Dwelling Adults Aged 40 Years and over with Type 2 Diabetes: Association with Self-Management Behaviors. Tang Z, Shen C, Tong W, Xiang X, Feng Z, Han B. Int J Environ Res Public Health. 2022;19(15):9092
17) Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.Jin S, Li Z, Yang Q, Fang B, Xiang X, Peng C, Cai W.Pharmaceutics. 2022 May 27;14(6):1141
18) Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs. Yuan Y, He Q, Zhang S, Li M, Tang Z, Zhu X, Jiao Z, Cai W, Xiang X (通讯作者). Front Pharmacol. 2022;13:895556.
19) Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. He Q, Bu F, Wang Q, Li M, Lin J, Tang Z, Mak WY, Zhuang X, Zhu X, Lin HS, Xiang X (通讯作者). Int J Mol Sci. 2022;23(9):4485.
20) Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.Jin Z, He Q, Zhu X, Zhu M, Wang Y, Wu XA, Lv Q, Xiang X (通讯作者).Basic Clin Pharmacol Toxicol. 2022;130(5):592-605.
21) The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy.Li J, Zhang G, Liu CG, Xiang X, Le MTN, Sethi G, Wang L, Goh BC, Ma Z.Theranostics. 2022;12(1):87-104.
22) Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib.Liu H, Yu Y, Guo N, Wang X, Han B, Xiang X (通讯作者).Front Pharmacol. 2021;12:780937.
23) Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study.Li M, He Q, Yao L, Wang X, Tang Z, Zhu X, Lin HS, Xiang X (通讯作者).Pharmaceuticals (Basel). 2021 Nov 20;14(11):1194. doi: 10.3390/ph14111194.
24) Systematic Study on a Quantitative Analysis of Multicomponents by Single Marker (QAMS) Method for Simultaneous Determination of Eight Constituents in Pneumonia Mixture by UPLC-MS/MS.Zhang H, Xie W, Liu J, Xiang X, Zhang S, Hu J, Yang J.J Anal Methods Chem. 2021 Nov 3;2021:8311588. doi: 10.1155/2021/8311588. eCollection 2021.
25) A Novel Method for Predicting the Human Inherent Clearance and Its Application in the Study of the Pharmacokinetics and Drug-Drug Interaction between Azidothymidine and Fluconazole Mediated by UGT Enzyme.Yuan Y, Zhang J, Fang B, Xiang X, Ma G, Zhang S, Zhu B, Cai W.Pharmaceutics. 2021;13(10):1734.
26) Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.Liu C, Xiang X(共同一作), Han S, Lim HY, Li L, Zhang X, Ma Z, Yang L, Guo S, Soo R, Ren B, Wang L, Goh BC.Cancer Lett. 2022;524:91-102.
27) Differentiation of Human Pluripotent Stem Cells Into Definitive Endoderm Cells in Various Flexible Three-Dimensional Cell Culture Systems: Possibilities and Limitations.Bogacheva MS, Harjumäki R, Flander E, Taalas A, Bystriakova MA, Yliperttula M, Xiang X (通讯作者), Leung AW, Lou YR.Front Cell Dev Biol. 2021;9:726499.
28) Celastrol in cancer therapy: Recent developments, challenges and prospects.Lim HY, Ong PS, Wang L, Goel A, Ding L, Li-Ann Wong A, Ho PC, Sethi G, Xiang X (通讯作者), Goh BC.Cancer Lett. 2021 Sep 8;521:252-267.
29) A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.Wang Z, Xiang X(共同一作), Liu S, Tang Z, Sun H, Parvez M, Ghim JL, Shin JG, Cai W.Drug Metab Pharmacokinet. 2021;39:100362.
30) Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, Xiang X, Xie P, Wu C, Kang L.Int J Pharm. 2021;606:120868.
31) Resveratrol for cancer therapy: Challenges and future perspectives.Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, Xiang X, Ho PC, Wang L, Ong PS, Goh BC.Cancer Lett. 2021;515:63-72.
32) Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?Weng J, Xiang X, Ding L, Wong AL, Zeng Q, Sethi G, Wang L, Lee SC, Goh BC.Semin Cancer Biol. 2021;74:105-120.
33) Prediction of oral hepatotoxic dose of natural products derived from Traditional Chinese medicines based on SVM classifier and PBPK modeling. Li S, Yu Y, Bian X, Yao L, Li M, Lou Y, Yuan J, Lin H, Liu L, Han B, Xiang X (通讯作者). Archives of Toxicology. 2021;95(5):1683-1701.（ESI高被引论文）
34) Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin HS, Xiang X (通讯作者).Pharmaceuticals 2021, 14, 198.
35) Simulation of the In Vivo Fate of Polymeric Nanoparticles Traced by Environment-Responsive Near-Infrared Dye: A Physiologically Based Pharmacokinetic Modelling Approach.Li L, He H, Jiang S, Qi J, Lu Y, Ding N, Lin HS, Wu W, Xiang X (通讯作者).Molecules. 2021;26(5):1271.
36) Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.Zhang M, Yao X, Hou Z, Guo X, Tu S, Lei Z, Yu Z, Liu X, Cui C, Chen X, Shen N, Song C, Qiao J, Xiang X, Li H, Liu D.Front Pharmacol. 2021;11:585021.
37) Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).Yuan J, Li M, Yu Y, Lee TY, Lv G, Han B, Xiang X (通讯作者), Lu ZK.Drugs Real World Outcomes. 2021;8(2):131-140.
38) Tiny miRNAs Play a Big Role in the Treatment of Breast Cancer Metastasis.Teo AYT, Xiang X, Le MT, Wong AL, Zeng Q, Wang L, Goh BC.Cancers (Basel). 2021;13(2):337.
39) Development, In Vitro and In Vivo Evaluation of Racecadotril Orodispersible Films for Pediatric Use. Wang B, Yang L, Wang B, Luo C, Wang Y, Wang H, Chen F, Xiang X (通讯作者). AAPS PharmSciTech. 2021;22(1):15
40) Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. Niu W, Li S, Jin S, Lin X, Zhang M, Cai W, Jiao Z, Xiang X (通讯作者).Br J Clin Pharmacol. 2021;87(7):2790-2806.
41) Validation of the Simplified Chinese Version of the Brief Diabetes Quality of Life (DQoL) Questionnaire Based on a Cross-Sectional Study.Tang Z, Jiang X, Hong L, Feng Z, He Q, Yuan J, Xiang X (通讯作者). Int J Environ Res Public Health. 2020 Nov 26;17(23):8792
42) The double-edged sword of H19 lncRNA: Insights into cancer therapy.Shermane Lim YW, Xiang X, Garg M, Le MT, Li-Ann Wong A, Wang L, Goh BC.Cancer Lett. 2021;500:253-262.
43) Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy. Ma Z, Wang LZ, Cheng JT, Lam WST, Ma X, Xiang X, Wong AL, Goh BC, Gong Q, Sethi G, Wang L.Antioxid Redox Signal. 2021;34(18):1484-1497.
44) Current Perceptions and Improvement Approaches of Pharmaceutical Care Capacity of Community Pharmacists: A Quantitative Analysis Based on Survey Data at Chinese Chain Pharmacies. Tang Z, Lhamu P, Ye H, Hong L, Xiang X (通讯作者). Int J Environ Res Public Health. 2020 ;17(20):E7482.
45) Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B-lymphoblastic leukaemia: Ma-Spore ALL 2010 study.Jiang N, Wang L, Xiang X（共同一作）, Li Z, Chiew EKH, Koo YM, Lee HS, Lin HP, Tan AM, Quah TC, Kham SKY, Goh BC, Ariffin H, Yeoh AE.Br J Clin Pharmacol. 2021 ;87(4):1990-1999.
46) Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.Zhang M, Yao X, Hou Z, Guo X, Tu S, Lei Z, Yu Z, Liu X, Cui C, Chen X, Shen N, Song C, Qiao J, Xiang X, Li H, Liu D.Front Pharmacol. 2021 Feb 12;11:585021.
47) Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach. Chen F, Liu H, Wang B, Yang Z, Chen Y, Yang L, Wang B, Jiao Z, Lin HS, Quan Y, Wang H, Xiang X (通讯作者). AAPS PharmSciTech. 2020;21(7):245
48) Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. Chen Fang, Liu Hongrui, Wang Bing, Yang Liuliu, Cai Weimin, Jiao Zheng, Yang Zhou, Chen Yusheng, Quan Yingjun, Xiang X (通讯作者), Wang Hao. Frontiers in Pharmacology, 2020, 10:1692.
49) Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Cheng Cui, Miao Zhang, Xueting Yao, Siqi Tu, Zhe Hou, Valerie Sia Jie En, Xiang X, Jing Lin, Ting Cai, Ning Shen, Chunli Song, Jie Qiao, Shun Zhang, Haiyan Li, Dong-yang Liu. Acta Pharmaceutica Sinica B, 2020,10(7):1216-1227.
50) A novel strategy for prediction of human plasma protein binding using machine learning techniques. Yawen Yuan, Shuo Chang, Zheng Zhang, Zhigang Li, Size Li, Peng Xie, Wai-Ping Yau, Haishu Lin, Weimin Cai, Yanchun Zhang, Xiang X (通讯作者). Chemometrics and Intelligent Laboratory Systems, 2020, 199: 103962
51) A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.Chong QY, Kok ZH, Bui NL, Xiang X, Wong AL, Yong WP, Sethi G, Lobie PE, Wang L, Goh BC.Pharmacol Res. 2020 Jun;156:104686.
52) Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health. Dai Y, Lim JX, Yeo SCM, Xiang X, Tan KS, Fu JH, Huang L, Lin HS. Mol Nutr Food Res. 2020; 64(2):e1900905.
53) Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave’s disease: a metabolomic approach. Li X, Yang J, Jin S, Dai Y, Fan Y, Fan X, Li Z, Yang J, Yau WP, Lin H, Cai W, Xiang X (通讯作者). Archives of Toxicology. 2020;94(1):231-244.
54) An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang X, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L.Proc Natl Acad Sci U S A. 2019 ;116(46):23264-23273.
55) A Sensitive HPLC-MS/MS Method for the Quantification of Selegiline in Beagle Dog Plasma: Application to a Pharmacokinetic Study. Liu H, Chen F, Wang B, Wang H, Jin S, Yang Z, Chen Y, Quan Y, Xiang X (通讯作者). Current Pharmaceutical Analysis. DOI : 10.2174/1573412915666190823102223
56) Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling.Li S, Yu Y, Jin Z, Dai Y, Lin H, Jiao Z, Ma G, Cai W, Han B, Xiang X (通讯作者).Biomed Pharmacother. 2019;119:109416.
57) Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury.Jin S, Li X, Fan Y, Fan X, Dai Y, Lin H, Cai W, Yang J, Xiang X(通讯作者). Basic Clin Pharmacol Toxicol. 2019;125(6):508-517.
58) Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, Yang J, Xiang X(通讯作者).Biomed Pharmacother. 2019;117:109095.
59) Establishment of rat liver microsome-hydrogel system for in vitro phase II metabolism and its application to study pharmacological effects of UGT substrates. Zhang Z, Ma G, Xue C, Sun H, Wang Z, Xiang X(通讯作者), Cai W. Drug Metab Pharmacokinet. 2019;34(2):141-147.
60) A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.Pharmaceutics. 2018;10(4):221
61) A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study.Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC. Pharmaceutics. 2018;10(3). pii: E123.
62) Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide. Xue CF, Zhang Z, Jin Y, Zhu B, Xing JF, Ma G, Xiang X, Cai WM. Acta Pharmacol Sin. 2018;39(9):1522-1532
63) Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.Dai Y, Tan ALC, Chen H, Ong PS, Xiang X, Wu J, Lin HS.J Pharm Biomed Anal. 2018;153:95-101.
64) Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, Zhuang X, Lin HS, Shin JG, Xiang X(通讯作者). Basic Clin Pharmacol Toxicol. 2018;122(3):331-340.
65) Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone. Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, Cai W, Tao T, Xiang X(通讯作者). Sci Rep. 2017 Jun 6;7(1):2829.（ESI高被引论文）
66) Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide. Tong S, Sun H, Xue C, Chen H, Liu J, Yang H, Zhou N, Xiang X(通讯作者), Cai W. Xenobiotica. 2018 Apr;48(4):368-375
67) A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling. Li J, Chai H, Li Y, Chai X, Zhao Y, Zhao Y, Tao T, Xiang X(通讯作者). PLoS One. 2016 Aug 1;11(8):e0160260.
68) Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang X, Cai WM. Acta Pharmacol Sin. 2015;36(5):614-26.
69) Application of a New Dynamic Model to Predict the In Vitro Intrinsic Clearance of Tolbutamide Using Rat Microsomes Encapsulated in a Fab Hydrogel. Zhou N, Zheng Y, Xing J, Yang H, Chen H, Xiang X, Liu J, Tong S, Zhu B, Cai W. Drug Metab Dispos. 2016;44(1):40-9.
70) Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Chen W, Yeo SC, Elhennawy MG, Xiang X, Lin HS. Anal Bioanal Chem. 2015;407(19):5793-801.
71) Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies. Ma G, Lin J, Cai W, Tan B, Xiang X, Zhang Y, Zhang P. J Pharm Biomed Anal. 2014;92:149-59.
72) Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. Xiang X, Backman JT, Neuvonen PJ, Niemi M.
Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):245-52.
73) No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M. Eur J Clin Pharmacol. 2011 Nov;67(11):1159-67.
74) High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen PJ, Niemi M. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):51-60.
75) VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Sandanaraj E, Lal S, Cheung YB, Xiang X, Kong MC, Lee LH, Ooi LL, Chowbay B. Drug Metab Pharmacokinet. 2009;24(4):365-75.
76) Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Pharmacogenet Genomics. 2009 Jun;19(6):447-57.
77) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ, Chowbay B. Cancer Sci. 2008 Apr;99(4):816-23.
78) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B. Pharmacogenomics. 2007 Jun;8(6):567-75.
79) Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Jada SR, Xiaochen S, Yan LY, Xiang X, Lal S, Zhou SF, Ooi LL, Chowbay B. Eur J Clin Pharmacol. 2007 Jun;63(6):555-63.
80) Pharmacogenetics of target genes across the warfarin pharmacological pathway.Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Clin Pharmacokinet. 2006;45(12):1189-200.
81) Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, Lee SC, Lim R, Zhou QY, Goh BC, Tan EH, Chowbay B. Pharmacogenet Genomics. 2006 Sep;16(9):683-91.
82) 宋丽君,刘杰, 相小强，刘丽坤，张洪亮，刘硕，陈雯，林洪生。中医药与酪氨酸激酶抑制剂联合应用的精准配伍探讨.现代中西医结合杂志,2022,31(22):3201-3206.
83) 卜凤娇,李玲,张琇雯，孙红，相小强，黄滔敏。重组人表皮生长因子滴眼液的处方合理性评价与分析.中国临床药学杂志,2022,31(11):824-827.
84) 卜凤娇,何庆烽,相小强，黄滔敏。口服抗新型冠状病毒肺炎药物奈玛特韦/利托那韦潜在的药动学相互作用.中国临床药学杂志,2022,31(08):631-636.
85) 邓洁,蒋品,相小强，万宏，陈春麟。蛋白降解靶向嵌合体分子的药动学研究进展[J].中国临床药学杂志,2022,31(07):554-560.
86) 林嘉蓥,金冠钦,何庆烽,相小强（通讯作者）。PD-1/PD-L1抑制剂免疫相关不良反应在临床试验中的应对策略[J].中国临床药学杂志,2022,31(04):315-320.
87) 焦正,李新刚,尚德为,董婧,左笑丛,陈冰,刘剑敏,潘雁,周田彦,张菁,刘东阳,李禄金,方翼,马广立,丁俊杰,赵维,陈锐,相小强,王玉珠,高建军,谢海棠,胡蓓,郑青山.模型引导的精准用药：中国专家共识(2021版).中国临床药理学与治疗学,2021,26(11):1215-1228.
88) 王小凤,何庆烽,李哲,相小强（通讯作者）.生理药动学模型应用于治疗性抗体研究进展[J].中国现代应用药学,2021,38(19):2453-2462.DOI:10.13748/j.cnki.issn1007-7693.2021.19.021.
89) 沈春英,仇茂珍,顾萌,相小强,韩冰,袁静.基于大数据的药物警戒研究：美国食品药品监督管理局的最新研究进展及对我国的启示[J].药学服务与研究,2021,21(05):389-391.
90) 李敏,李思泽,姚莉,相小强（通讯作者）.数学模型预测药源性肝损伤研究进展.中国药理学与毒理学杂志,2021,35(05):382-390.
91) 卜凤娇,陈锦如,丁宁,焦正,相小强（通讯作者）.洛匹那韦/利托那韦与他汀类药物药动学相互作用研究进展.中国药学杂志,2021,56(12):957-962.
92) 王晓文,何庆烽,相小强,韩冰.生理药代动力学模型预测抑酸药物所致药物相互作用的研究进展。药学学报: 2021, 56(8): 2197 −2203
93) 姚莉,杨公炜,李敏,丁宁,相小强（通讯作者）。生理药代动力学模型在药物基因组学中的应用。中国临床药理学杂志,2021,37(04):487-489.
94) 姚莉,李思泽,李敏,丁宁,相小强（通讯作者）。生理药代动力学模型在天然药物药动学研究中的应用。世界科学技术-中医药现代化,2020,22(12):4147-4153.
95) 陈文君,阮邹荣,相小强（通讯作者）。生理药代动力学模型的发展应用动态及其与其他建模方法的融合。中国临床药理学与治疗学,2020,25(03):299-305.
96) 郑晓洁，李思泽，袁雅文，金莎莎，李敏，相小强（通讯作者）。儿童生理药代动力学模型及其在儿科药物研究中的应用。药学学报,2020,55(01):38-44.
97) 王冰，刘宏锐，陈芳，全应军，王浩，相小强（通讯作者）。口腔黏膜给药系统的药物动力学研究进展.药学学报,2020,55(02):226-234.
98) 刘宏锐，陈芳，相小强，全应军，金莎莎。生理药代动力学建模在药剂学中的应用。中国医药工业杂志，2019, 50(4)：383-391
99) 刘东阳，王鲲，马广立，相小强，刘江，赵平，陈锐，陈渊成，黄晓晖，李丽，李禄金，聂晶，王玉珠，魏春敏，卢炜，史军，李改玲，杨进波，王亚宁，郑青山，胡蓓。新药研发中定量药理学研究的价值及其一般考虑（专家共识）。中国临床药理学与治疗学，2018, 23(9)：961-973
100) 金莎莎，王琪珍，卜凤娇，相小强（通讯作者），肠道微生态对药物代谢的影响。上海医药，2018，39（15）：22-24
101) 刘晓芹，蒋馨莹，胡文清，马国，蔡卫民，侯爱君，相小强（通讯作者）。标准化病人在临床药学教育中的应用。中国临床药学杂志，2017，26（4）：258
102) 卜凤娇，蒋品，张洪艳，相小强（通讯作者）。以五味子为例的多来源药材品种鉴别研究进展。时珍国医国药杂志，2015，26（11）：2734-2736
103) 相小强, 陶涛, 陈庆华。透血脑屏障制剂的研究进展。中国新药杂志，2002;11(7):519-523.
104) 范田园，魏树礼, 相小强,等。盐酸地尔硫卓压制包衣脉冲片的研究。中国药学杂志, 2000;35(5):317-320.
发表著作或教材
（1）《Pharmacogenomics in Precision Medicine: From aPerspective of Ethnic Differences》，主编，出版社：Springer，ISBN: 978-981-15-3895-7，2020年6月12日出版
（2）《DEXTROMETHORPHAN: Pharmacology, Clinical Uses andHealth Effects》，参编，NovaScience Publishers, Inc. ， 2015年第1版
（3）《临床药物治疗学·总论》，参编，人民卫生出版社，2017年1月1日第1版，ISBN：9787117227469
（4）《药理学》(“博学.尚医”基础医学核心课程系列教材)，参编，复旦大学出版社，2016年6月1日第1版，ISBN：978-7-309-11727-1/R.1497
（5）《临床药学导论》，参编，科学出版社，2017年7月第1版，ISBN： 978-7-03-053001-1
（6）《小细菌大健康：现代社会慢病微生态健康管理》，副主编，复旦大学出版社; 2017年11月1日第1版
授权发明专利
1. 相小强，袁雅文，张政，常硕，张彦春，李治纲，蔡卫民，田凌浩。一种基于结构和等级分类的药物蛋白结合率预测方法及系统。CN110689919B，2023-03-17授权。
3. 相小强，李敏，张政，李治纲，刘海树，蔡卫民，田凌浩。基于结构及药代动力学的物质结构优化指导方法和系统。CN110648725B，2023-06-16授权。
学术兼职
（1）中国药理学会定量药理专业委员会常务委员
（2）中国药理学会药物代谢专业委员会委员
（3）中国药理学会表观遗传药理专业委员会委员
（4）中国药理学会治疗药物监测研究专业委员会定量药理学组委员
（5）中国药学会中医肿瘤药物与临床研究专业委员会委员
（6）上海药理学会药物代谢专业委员会副主任委员
（7）上海药理学会临床药理专业委员会委员
（8）《药学学报》中英文刊编委
（9）《药物不良反应杂志》编委
（10）《中国临床药学杂志》编委
（11）上海药学会监事
参编中国专家共识
(1)《模型引导的精准用药：中国专家共识(2021版)》
(2)《新药研发中定量药理学研究的价值及其一般考虑（专家共识）》导原则》
所获奖励
（1）2020年度一健康基金优秀教师常规奖三等奖
（2）2019年度“复旦大学第一三共制药奖教金”
（3）上海医学院课程思政教案大赛一等奖
（4）复旦大学2017年教学成果一等奖：“临床药学人才培养模式的探索与创新”
（5）复旦大学药学院2017届毕业生“我心目中的好老师”
（6）2014年度药学院青年教师讲课比赛二等奖
